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We report for the first time that pasireotide was successfully used in
the treatment of adult nesidioblastosis.
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Abstract: Nesidioblastosis is a rare cause of endogenous hyperinsu-
linemic hypoglycemia in adults. Diagnosis is often challenging and
therapeutic options are scarce.
In 2009, a 46-year-old female patient presented with recurrent
severe hypoglycemia and immediate recovery after glucose ingestion.
Although 72-h-fasting test was positive, various imaging technologies
(sonography, computed tomography, somatostatin receptor scintigra-
phy, dopamine receptor positron emission tomography [DOPA-PET])
were negative. Endoscopic ultrasound revealed a lesion in the pancreatic
corpus, whereas selective arterial calcium stimulation test, portal venous
sampling and GLP-1-receptor scintigraphy were indicative of a lesion in
the pancreatic tail, which was surgically removed. The histopathologic
examination revealed beta cell hyperplasia and microadenomas expres-
sing glucagon. After surgery, the patient was free of symptoms for 6
months, after which hypoglycemic episodes recurred. After unsuccess-
ful treatment with corticosteroids and somatostatin analogs, treatment
with pasireotide, a novel somatostatin analog with high affinity to
somatostatin receptor 5 and a possible side effect of hyperglycemia,
was initiated (0.6mg BID). To date, our patient has been free of severe
hypoglycemic episodes ever since. Yearly repeated imaging procedures
have shown no abnormities over the last 3 years.as R. Pieber, MD, er, MD,
Julia K. Mader, MD
(Medicine 95(14):e3272)
Abbreviations: ACTH = adrenocorticotropic hormone, CGM =
continuous glucose monitoring, DOPA-PET = dopamine receptor
positron emission tomography, GLP-1 = glucagon-like peptide-1,
H&E = hematoxylin and eosin staining, LAR = long-acting release,
MEN-1 = multiple endocrine neoplasia type 1, MRI = magnetic
resonance imaging, NIPHS = non-insulinoma pancreatogenous
hypoglycemia syndrome, SACST = selective arterial calcium
stimulation test, SRIF = somatotropin release-inhibiting factor
(somatostatin), SSTR = somatostatin receptor subtypes.
INTRODUCTION
N esidioblastosis is a condition with diffuse hyperplasia ofthe pancreatic islets, leading to hyperinsulinemic hypo-
glycemia. It is the most important differential diagnosis to
insulinoma in the adult, but only 0.5% to 5.0% of the
cases with hyperinsulinemic hypoglycemia can be attributed
to noninsulinoma pancreatogenous hypoglycemia syndrome
(NIPHS),1,2 which is currently more often seen in patients
who have undergone bariatric surgery.
To fulfill the diagnostic criteria, detection of endogenous
hyperinsulinemic hypoglycemia, positive selective arterial
calcium stimulation test (SACST),3 and negative imaging stu-
dies are required after exclusion of artificial causes of hypo-
glycemia such as inappropriate use of insulin or sulfonylurea.
Nonetheless, the results of the above-mentioned examsmight be
inconclusive, that is, small insulinomas might not be detected in
imaging studies or large hyperplastic areas showing large
gradients in SACST might be interpreted as insulinoma. Thus,
the final diagnosis can only be established after histopathologic
examination.
In mild cases, dietary modifications (low carbohydrate
diet) might be sufficient to resolve symptoms.4 Pharmacologi-
cal treatment options include diazoxide, acarbose, corticoster-
oids, verapamil, and octreotide. In patients developing severe
symptoms partial or total pancreatectomy might be required.
Here we report a case of a patient with nesidioblastosis
successfully treated with pasireotide, a somatostatin analog with
high affinity for somatostatin receptor 5, originally developed
for the treatment of Cushing’s disease. For the herein presented
case, the patient has provided written informed consent for
publication.
Clinical Case
In 2009, a 46-year-old woman was admitted with a blooddL (2.1mmol/L). Even upon intravenous
ich diet, glucose levels did not exceed
). The patient’s history revealed fatigue,
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sweating, craving for sweets over the last months and weight
gain of 5 kg in 1 year. Insulinoma was suspected.
By performing an oral glucose tolerance test, reactive
postprandial hypoglycemia could be ruled out. A consecutive
72 hours fast showed a decline in glucose to 34mg/dL
(1.9mmol/L) after 14 hours of fasting. At that time the insulin
level was inadequately in the normal range (13.0mU/mL,
normal range: 2.0–25.0mU/mL) and C-peptide was elevated
(8.2 ng/mL, normal range: 0.78–1.89 ng/mL), indicative of
autonomous insulin secretion.
Imaging procedures including abdominal ultrasound, mag-
netic resonance imaging (MRI), computed tomography scan
(CT scan), fluorodeoxyglucose positron emission tomography
(FDG-PET), dopamine receptor positron emission tomography
(DOPA-PET), octreotide receptor scintigraphy, and diagnostic
laparotomy with palpation of the pancreas revealed no
pathological findings.
Selective arterial calcium stimulation test (SACST) with
hepatic venous sampling to determine the localization of hyper-
insulinemia within the pancreas,5,6 showed a 2.1-fold, positive
increase in insulin (>2)5,6 measured in the hepatic vein after
calcium injection in the great pancreatic artery. In patients with
NIPHS, an increase in insulin is usually observed after injection
of multiple arteries, in patients with insulinoma the response
would be expected to be positive in 1 artery alone.
In endoscopic ultrasound a hypoechogenic lesion in the
pancreatic corpus at the height of the confluens could be
located. As the results were inconclusive with regard to the
localization of the lesion, portal venous sampling was addition-
ally performed to differentiate localized (solitary insulinoma)
from diffuse hyperinsulinism caused by adenomatosis, hyper-
plasia, and nesidioblastosis.2 It was indicative of an increased
insulin secretion in the tail of the pancreas.
This was confirmed by glucagon-like peptide-1 (GLP-1)
receptor scintigraphy showing an increased uptake not only in
the head (physiologic) but also in the tail of the pancreas
(Figure 1 A and B). Subsequently, distal pancreatectomy was
performed, histopathologic examination of the pancreatic tail
revealing hyperplasia of the islets of Langerhans (Figure 2).
In addition, neuroendocrine microadenomas with immu-
nohistochemical staining for glucagon in all of the adenoma
cells were present (Figure 3). Co-occurrence of adult nesidio-
blastosis with microadenomas composed of alpha cells
(Figure 3) without elevation of serum glucagon, as measured
on several occasions in the presented case, (Figure 2C) has to
Schwetz et al.the best of our knowledge not been described in the literature so
far. Subsequent genetic testing for multiple endocrine neoplasia
type 1 (MEN-1) was negative.
FIGURE 1. Glucagon-like peptide-1 (GLP-1) receptor scintigraphy show
2 | www.md-journal.comDuring the first 6 months following distal pancreatectomy,
the patient was free of hypoglycemic symptoms. After 6
months, symptoms of endogenous hyperinsulinism including
hypoglycemia started to reappear. As the patient was hesitant
toward any further surgical procedure, conservative medical
therapy including administration of corticosteroids, everolimus,
and octreotide was initiated; however, all medical treatment
approaches were futile. Yearly diagnostic imaging follow-up
including abdominal ultrasound, MRI, octreotide receptor
scintigraphy, and DOPA-PET repeatedly showed no
pathological finding.
Over time, hypoglycemia unawareness developed. Sub-
sequently, in the beginning of 2012, the patient was equipped
with a continuous glucose monitoring (CGM) system (Guardian
RT, Medtronic-Minimed, Northridge, CA) to alert her timely to
prevent severe hypoglycemia.
In the attempt to alleviate the burden of disease, pasireotide
0.6mg twice daily was initiated in November 2012. Pasireotide
is a somatostatin analog with a 40-fold increased affinity to
somatostatin receptor 5 compared to other somatostatin analogs
and is used in the treatment of Cushing’s disease and acrome-
galy. It is known to suppress insulin secretion and thus to cause
hyperglycemia as one of its most concerning side effects.7
Pasireotide has been successfully applied in patients suffering
from dumping syndrome with hypoglycemia.8 Also, treatment
with pasireotide in patients with severe post Roux-en-Y gastric
bypass hyperinsulinemic hypoglycemia has been suggested.9
To the best of our knowledge, pasireotide has never been used in
adult nesidioblastosis so far.
After the first administration of pasireotide, glycemic
levels started rising immediately, the carbohydrate require-
ments decreased, and the observed hypoglycemic levels were
milder in their extent and mainly above the commonly accepted
threshold for hypoglycemia (above 56mg/dL [3.1mmol/L])
(Table 1). The glycemic response to pasireotide was monitored
with CGM (Figure 4). The substance was well tolerated with
only mild nausea that could be successfully treated with
ondansetron. When comparing the CGM values prior to and
2 weeks following initiation of pasireotide therapy a significant
increase in glycemia, reduced time in hypoglycemia, and
increased time in eu- and even hyperglycemia could be
observed. Mean sensor glucose increased from 74  16mg/
dL (4.1 0.9mmol/L) to 103 23mg/dL (5.7 1.3mmol/L).
The patient has been successfully treated with pasireotide
for 3 years now with marked improvement in quality of life.
Medicine  Volume 95, Number 14, April 2016Pasireotide treatment is—except for intermittent mild nausea—
well tolerated and the patient has not experienced any severe
hypoglycemic episode ever since. ACTH and cortisol were
ing an increased uptake both in the head and tail of the pancreas.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 2. Microadenoma and enlarged LH islet: (A) H&E; (B) synaptophysin; (C) insulin; (D) glucagon. (A) Microadenoma in the vicinity
of an enlarged LH islet (H&E). (B) The endocrine cells of the microadenoma and the LH islet stain with antibodies against synaptophysin.
(C) The majority of the cells of the LH islet are positive, whereas most of the cells of the microadenoma are not labeled with insulin
antibodies (D) but are positive with antibodies against glucagon. In contrast in the LH islet only the alpha cells are glucagon positive; scale
bars indicate 100mm.
FIGURE 3. Nesidioblastosis with increased numbers enlarged of Langerhans islets (A–D): (A) H&E; (B) insulin; (C) glucagon; (D) SRIF
(somatotropin release-inhibiting factor). (A) Increased number of enlarged Langerhans islets (H&E). (B) The islets consist of mainly of
ß-cells (60–70%) which are labeled with antibodies directed against insulin. (C) Approximately 10% to 15% of the islet cells are decorated
by antibodies against glucagon and (D) some islet cells are positive with antibodies against somatostatin. Scale bars indicate 100mm.
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and GLP-1 more efficiently than octreotide resulting in a better
control of postprandial hyperinsulinemic hypoglycemia.9 Inhi-
bition of insulin secretion by islet beta cells is mediated by
TABLE 1. Levels of Hypoglycemia Assessed by Continuous Glucose Monitoring the Last 14 days Before Initiation of Pasireotide as
Compared to the First 14 Days Using Pasireotide
14 d Before Pasireotide 14 d Using Pasireotide
P ValueMinutes % Minutes %
Active CGM 19,755 98.0 17,825 88.4 –
<70 mg/dL (<3.9 mmol/L) 7955 40.3 2395 13.4 <0.001
<58 mg/dL (<3.2 mmol/L) 1660 8.4 495 2.8 <0.001
<56 mg/dL (<3.1mmol/L) 1230 6.2 380 2.1 <0.001
50 mg/dL (2.8mmol/L) 755 3.8 155 0.9 <0.001
<50 mg/dL (<2.8 mmol/L) 560 2.8 60 0.3 <0.001
<45 mg/dL (<2.5 mmol/L) 410 2.1 0 0.0 <0.001
hich
luc
TABLE 2. Levels of ACTH (Adrenocorticotropic Hormone) and
Cortisol Were Monitored on a Regular Basis and Did Not Show
Any Clinically Significant Abnormalites
Schwetz et al. Medicine  Volume 95, Number 14, April 2016controlled regularly and have been in the normal range
(Table 2). Imaging procedures (MRI, somatostatin receptor
scintigraphy, 18F-DOPA-PET) were performed in yearly inter-
vals and showed no abnormities over time.
DISCUSSION
We present a case of nesidioblastosis with microadenomas
expressing glucagon with recurrent hypoglycemic episodes
after partial pancreatectomy unresponsive to usual therapeutic
approaches. Only initiation of therapy with pasireotide has re-
established and maintained normoglycemia and a good quality
of life for the affected patient for a total of 3 years.
Pasireotide is a somatostatin analog targeting 4 out of the 5
somatostatin receptor subtypes (SSTR) with the highest affinity
for sst1 and sst5. The affinity for sst5 is 40-fold higher com-
pared to octreotide.10 Pasireotide has shown to effectively
inhibit ACTH and corticosterone secretion both in vitro and
in vivo11,12 and has proven effective in the treatment of Cush-
ing’s disease.7,13 Although responders to pasireotide treatment
showed decreased plasma ACTH and cortisol levels, increases
in blood glucose and glycated haemoglobin levels were
The 2 periods were compared by means of Pearson’s chi-square test, w
hypoglycemic ranges between periods, respectively. CGM continuous gobserved; 46% of the treated patients in that specific study
even required initiation of diabetes therapy.13 A study in healthy
volunteers also reported elevated blood glucose levels 2 to
FIGURE 4. Mean sensor glucose level over a 14-day period prior
to (gray line) and immediately after (black line) initiation of
pasireotide treatment.
4 | www.md-journal.com6 hours after single doses of pasireotide (200–1200mg) which
resolved within 23 hours after dosing. The described effect was
more pronounced at higher doses of 600 to 1200mg pasireo-
tide.14 In a mechanistic clamp study, Henry et al demonstrated
that hyperglycemia induced by pasireotide administration is
caused by decreased insulin secretion and incretin hormone
responses, without influencing the hepatic and/or peripheral
insulin sensitivity.15 From the beginning we could observe the
described effects of pasireotide on glycemia14,15 in our patient
in support of previous studies showing effective application of
pasiretoide in dumping syndrome8 and in a patient with post-
prandial hyperinsulinemic hypoglycemia following Roux-en-Y
gastric bypass.9 In the latter patient, pasireotide inhibited insulin
provided a statistically significant difference (P< 0.001) for each of the
ose monitoring.Time Point Cortisol (ng/mL) ACTH (pg/mL)
Q1/2010

169.2 18.6
Q4/2012

107.5 19.1
Q4/2012 88.9 17.6
Q4/2012 101.0 15.2
Q4/2012 134.4 21.6
Q1/2013 100.3 14.0
Q2/2013 114.1 20.5
Q3/2013 163.2 19.2
Q4/2013 174.6 22.8
Q1/2014 139.2 18.9
Q2/2014 174.4 23.4
Q3/2014 – 35.8
Q4/2014 – 28.3
Q1/2015 200.8 36.5
Q2/2015 246.8 38.7
Q3/2015 148.1 20.3
Q4/2015 243.0 43.0

Laboratory before the start of pasireotide. The normal ranges
for ACTH were 43 to 220 ng/mL and for cortisol 10 to 51 pg/mL,
respectively.
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somatostatin receptor 2 (SSTR2) and 5 (SSTR5). Glucagon
inhibition from alpha cells is mediated almost entirely by
SSTR2. As the affinity of pasireotide to SSTR5 is much higher
than to SSTR2,16 pasireotide suppresses mostly insulin.
Another factor in the avoidance of severe hypoglycemia
achieved by pasireotide might be its suppression of GLP-1,
as suggested by de Heide.9
Another effect of pasireotide rendering it successful in the
treatment of neuroendocrine tumors could be its direct and
indirect antitumor effects mediated via SSTR, such as apoptosis
and inhibition of cell proliferation.17–19 In patients with
advanced neuroendocrine tumors refractory or resistant to
octreotide LAR therapy, pasireotide treatment was effective
and well-tolerated in controlling symptoms of carcinoid syn-
drome in 27% of patients and resulted in stable disease in more
than half of the patients.20
Consistent with these data, pasireotide has been well
tolerated by our patient for >3 years now. According to the
regularly monitored CGM signal—the availability of which
being one of the strengths of this case, hypoglycemia is well
controlled and the patient is in euglycemia the majority of the
time. Further, as seen in the regularly performed imaging
studies (MRI, somatostatin receptor scintigraphy, DOPA-
PET), the discreet tracer uptake in DOPA-PET, indicating that
beta cell hyperplasia is still present, has remained stable. There
has also been no growth of the pancreas following distal
pancreatectomy, as seen in MRI. This is in line with the tumor
control described by Kvols and colleagues.20
Another unusual feature in this case was the co-occurrence
of nesidioblastosis and microadenomas consisting of alpha
cells, which to the best of our knowledge has not yet been
reported so far in adults. Although genetic testing could rule out
MEN1 syndrome, we cannot exclude that other, so far unknown
mutations could play a role in the pathogenesis of the micro-
adenomas in our patient. Finally, it may be speculated that
regulatory mechanisms against the effects of nesidioblastosis
could be involved in hyperplasia of alpha-cells and the for-
mation of microadenomas; these, however, are insufficient to
counteract hyperinsulinism and hypoglycemia in the present
case.
Data from the patient presented here and from the case
report by de Heide bring up the question as to the significance of
pasireotide in the treatment of patients with NIPHS post-bar-
iatric surgery in the future. The numbers of patients undergoing
bariatric surgery are rising, consecutively causing higher rates
of nesidioblastosis. Especially in these patients pasireotide
might be an interesting treatment option, as re-surgery might
cause numerous complications including adhesions. Further,
these patients are at higher general risk due to their overweight.
However, further data are needed before pasireotide can be
recommended as a treatment option in different scenarios of
autonomous endogenous hyperinsulinemic hypoglycemia.
Expectations are raised, though, after successful application
of pasireotide in postprandial hyperinsulinemic hypoglycemia
after Roux-en-Y gastric bypass and upon the first successful
long-term treatment with pasireotide of a patient with recurrent
hypoglycemic episodes due to adult nesidioblastosis presented
here.
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